(VCBeat) Apr. 21, 2021 -- SceneRay Co., Ltd., a leading domestic medical device company focusing on the development and production of deep brain stimulation (DBS) system, announced the completion of a Series D funding round of over 100 million yuan, led by Yanchuang Capital, with participation from DYEE Capital, Tahoe Capital, Shanghai Yehao and others. China Renaissance acted as the exclusive financial adviser for this transaction.
The funds raised will be mainly used for the development and clinical trials for new indications of SceneRay's existing DBS products under development, and the marketing and commercialization of the listed product line. In the future, the company will continue to provide more overall solutions for clinical treatment and better benefit the vast number of Parkinson's disease patients in China.
Founded in 2009, SceneRay is an innovative high-tech medical device company integrating R&D, production, and sales of DBS systems. SceneRay has gathered excellent talents from Tsinghua University, Peking University, Jiaotong University, Fudan University and overseas returnees to build a professional R&D team. According to market changes, SceneRay continues to carry out technological innovation and product R&D. It has obtained more than 200 domestic patents and more than 10 international patents.
In the frontier field of neuroscience, SceneRay has made outstanding achievements by virtue of its core technology and independent R&D capabilities and will continue to deeply empower the industry reform with its leading technology in the future.
Since 2012, SceneRay cooperated with Professor Gao Guodong of Air Force Military Medical University to develop a drug-reducing brain-computer chip and a drug-reducing DBS system based on theoretical and technological innovations in addiction mechanisms, committed to solving the high relapse after drug addiction. A single-center detoxification clinical trial has been completed and breakthrough results have been achieved. This detoxification brain pacemaker is the world's first medical device with multi-targets combined regulation in the brain for drug addiction and treatment of mental illness.
At present, SceneRay's detoxification DBS system is undergoing strict national standard (prospective, multi-center, double-blind, randomized controlled) national multi-center clinical trials, which has further verified its therapy.
About Yanchuang Capital
Founded in June 2010, Yanchuang Capital is a high-tech investment and capital operation platform jointly initiated by alumni of Peking University and alumni enterprises engaged in venture capital investment and the transformation of university technological achievements under the advocacy and support of the Science and Technology Development Department of Peking University.
At present, Yanchuang Capital has three business segments, namely equity investment, securities investment, listed company cooperation & merger and reorganization, with an AUM of more than 6 billion yuan.
About DYEE Capital
DYEE Capital is a private equity & venture capital firm. Founded in June 2016, DYEE Capital focuses on modern services and investing in medical care, information services, consumption upgrading, and other fields.